@entity11756 in the management of new-onset XXXX after renal transplantation.

@entity1 @entity6 @entity11756 @entity15157 @entity205 @entity4854 @entity1011 @entity1140 @entity6170 @entity413
The purpose of this study was to investigate the use of the short-acting insulin secretion drug @entity11756 in new-onset @entity6 (NODM) after renal transplantation. Twenty-three Caucasian @entity1 with NODM after renal transplantation were selected to receive @entity11756 therapy and were followed for at least 6 months. A control group treated with @entity6170 was chosen for comparison. Successful @entity11756 treatment was defined as a significant improvement of blood @entity413 concentrations and HbA1c <7% in the absence of @entity15157 and without the need for the addition of further anti- @entity6 agents. After 6 months of treatment with @entity11756 , 14 of the 23 @entity1 were successfully treated. Mean HbA1c decreased from 7.6 +/- 0.6% to 5.8 +/- 0.6% in 14 @entity1 treated successfully. In nine @entity1 , @entity4854 persisted, and they were switched to insulin treatment (HbA1c 8.5 +/- 2.9% at the beginning to 7.4 +/- 2.2%). Mean serum @entity1011 levels, @entity205 and @entity1140 blood levels did not change significantly following institution of @entity11756 therapy. The rate of successful treatment and the degree of HbA1c decrease were similar compared to @entity6170 -treated control @entity1 . The data from our observational study indicate that @entity11756 can be an effective treatment option in Caucasian @entity1 with NODM after renal transplantation.
